Irritable Bowel Syndrome (IBS)

Introduction and Definition of Irritable Bowel Syndrome

Irritable bowel syndrome (IBS) is classified as a functional gastrointestinal (GI) disorder. In the medical context, a functional GI disorder is defined as a condition for which no organic or structural cause has been identified despite clinical investigation. IBS is specifically defined by the presence of chronic abdominal pain associated with altered bowel habits. Depending on the primary symptomatic presentation, the condition is categorized into three subtypes: constipation-predominant (IBS-C), diarrhea-predominant (IBS-D), or mixed (IBS-M), where patients vacillate between both constipation and diarrhea.

Case Study: BD

BD is a $27$-year-old female patient seeking a second opinion regarding persistent abdominal pain. She reports that her pain occurs on a daily basis and has confirmed that it is not related to her menstrual cycle. Her bowel habits are inconsistent; she describes periods of constipation interspersed with periods of diarrhea. Despite the severity of her symptoms, a battery of diagnostic tests has yielded normal results. These tests include comprehensive bloodwork, a CT scan, a pelvic ultrasound, a colonoscopy, and an upper GI endoscopy. She was also specifically tested for celiac disease, which was negative. Her last CT scan was performed $1$ year ago, and she expresses a belief that she needs another one, stating, ‘Something must be wrong for me to have all this pain all the time.’ Upon physical examination, her abdominal and pelvic assessments are entirely normal. The physician notes that her symptoms are consistent with Irritable Bowel Syndrome, and the first line of treatment involves lifestyle modifications such as physical exercise and a low-FODMAP diet. The physician emphasizes the importance of reassuring the patient that previous testing was necessary to rule out other pathologies, but that a diagnosis of IBS is now confident.

Clinical Presentation and Red-Flag Features

The clinical presentation of IBS typically involves abdominal pain and cramping, distinct changes in bowel habits, and bloating. However, some patients may also manifest systemic symptoms, including nausea, lethargy, and back pain. While IBS itself is a functional disorder, clinicians must remain vigilant for "red-flag" features that suggest more serious underlying organic pathology. These red flags include unintentional weight loss, rectal bleeding, and the new onset of IBS-like symptoms in an elderly patient. In the absence of these signs, and when the patient meets specific diagnostic thresholds, a clinical diagnosis can be established.

Diagnostic Criteria: The Rome IV Standards

The diagnosis of IBS is standardized using the Rome IV diagnostic criteria. According to these guidelines, IBS is defined by recurrent abdominal pain that averages at least $1$ day per week for a duration of at least $3$ months. This pain must be associated with at least two or more of the following criteria: the pain is related to defecation, it is associated with a change in the frequency of stool, or it is associated with a change in the appearance (form) of stool.

Pathophysiology of Irritable Bowel Syndrome

Although the exact cause of IBS remains unknown and multiple factors are implicated, several physiological mechanisms have been identified as contributors to the condition. A primary factor is gastrointestinal dysmotility, which refers to the impairment of the normal synchronized contraction and relaxation of GI muscles. In patients with IBS-C, there is a measurable prolonged transit time of bowel contents. Conversely, in patients with IBS-D, there is often an exaggerated response to cholecystokinin. This response includes increased pancreatic secretions, increased gallbladder contraction, and decreased gastric emptying. GI dysmotility may manifest as disorganized or extreme contractions, varying in coordination, speed, and strength, though this is not present in all patients.

Another significant component of IBS pathophysiology is visceral hypersensitivity, characterized by an increased sensation or sensitivity in response to various stimuli within the GI tract. The gut wall contains numerous receptors that transmit nerve signals via afferent pathways to the dorsal horn of the spinal cord and then to the brain. In IBS, it is hypothesized that heightened sensitivity arises somewhere along this pathway. Certain neurotransmitters, specifically kinins and $\text{serotonin}$, are thought to play a role. These substances can increase spinal cord excitability by activating glutamate (NMDA) receptors, which predisposes the patient to an increased perception of pain. Other potential mechanisms currently under investigation include intestinal inflammation, previous infections, and alterations in the fecal microbiota.

Risk Factors and Psychosocial Associations

Several risk factors are associated with an increased likelihood of developing IBS. There is a strong correlation between mental health illnesses and the syndrome; patients suffering from depression or anxiety exhibit a higher risk. Furthermore, a history of childhood abuse is identified as a significant risk factor. IBS is also frequently co-morbid with other chronic pain conditions, such as fibromyalgia and migraines.

Differential Diagnosis and Clinical Correlations

Because there are no definitive diagnostic tests for IBS, the diagnostic work-up is largely focused on ruling out alternative conditions that present with similar symptoms. These include inflammatory bowel disease (IBD), celiac disease, lactose intolerance, colorectal cancer, and diversas food sensitivities.

Inflammatory bowel disease (IBD) is a critical differential, representing a group of chronic autoimmune diseases. It includes Ulcerative Colitis (UC), which is characterized by continuous mucosal inflammation that starts in the rectum and moves proximally, affecting only the inner lining of the large bowel. The second major form is Crohn disease, which is a transmural disease affecting the entire thickness of the bowel wall. Crohn disease can affect any part of the GI tract from the mouth to the anus, though it most commonly targets the terminal ileum. Unlike IBS, both forms of IBD can have extraintestinal manifestations and involve visible inflammation or ulceration.

Diagnostic Procedures and Laboratory Testing

Laboratory testing in suspected IBS is used to exclude organic disease rather than to confirm IBS. A normal complete blood count (CBC) is utilized to rule out iron-deficiency anemia, which might suggest occult GI bleeding. Stool tests for ova and parasites may be performed to rule out infectious causes. To assess for intestinal inflammation, physicians may test for C-reactive protein (CRP) and fecal calprotectin. Fecal calprotectin is a protein complex specifically indicating the migration of neutrophils to the intestinal mucosa, a hallmark of IBD. Normal levels of these markers, along with a normal white blood cell count and a normal colonoscopy, support an IBS diagnosis. In specific cases, a hydrogen lactose breath test or testing for gluten enteropathy antibodies may be conducted to rule out lactose intolerance or celiac disease, respectively.

Therapeutic Management and Lifestyle Modifications

The management of IBS relies heavily on a strong clinician-patient relationship characterized by continuity of care, patient education, and reassurance. It is essential for clinicians to validate the patient's concerns and the burden the disease places on their lifestyle while reassuring them that IBS does not increase the risk of malignancy.

When symptoms are intermittent, lifestyle and dietary modifications are the first-line recommendations. Regular physical exercise has been shown to help mitigate symptoms. From a dietary perspective, patients are encouraged to avoid gas-producing foods, specifically those high in FODMAPs (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, And Polyols). Specific examples of foods to avoid include:

• Oligosaccharides: Wheat, barley, onion, garlic, cashews, legumes, lentils, and chickpeas.
• Disaccharides: Milk, yogurt, ice cream, and custard.
• Monosaccharides: Honey, high-fructose corn syrup, and peaches.
• Polyols: Apples, cherries, watermelons, and plums.

Dietary restrictions are typically applied on a case-by-case basis; for instance, gluten is only avoided if the patient's symptoms are specifically related to gluten consumption.

Pharmacological Interventions

Pharmacological treatment is reserved for cases where lifestyle and dietary modifications are insufficient.

For IBS-C, recommended treatments include:

• Fiber supplementation, specifically with psyllium.
• Guanylate cyclase agonists, such as linaclotide and plecanatide, which stimulate intestinal fluid secretion and transit.
• Lubiprostone, a locally acting chloride channel activator that increases intestinal fluid secretion.
• Standard laxatives.

For IBS-D, recommended treatments include:

• Alosetron, a $5HT-3$ (serotonin) receptor antagonist.
• Antidiarrheal agents such as loperamide.
• Bile-acid sequestrants.
• Eluxadoline, which acts as a mixed mu opioid receptor agonist and $\delta$ opioid receptor antagonist.
• Rifaximin, an antibiotic.

General symptom management may involve antispasmodics like dicyclomine or hyoscyamine, and in some cases, tricyclic antidepressants are utilized to modulate pain perception.

Questions & Discussion

Question 1: A $25$-year-old female presents with abdominal bloating and diffuse pain that fluctuates and improves with defecation. She has experienced these symptoms for $4$ months, occurring every other day. She notes milk and grains worsen her symptoms. CBC, fecal calprotectin, hydrogen lactose breath test, gluten antibodies, colonoscopy, and endoscopy are all normal. What is the most likely diagnosis? Answer: Irritable bowel syndrome (IBS).

Question 2: A $27$-year-old female with a history of IBS-C finds no improvement with dietary modification. Which medication can be used for her constipation? Answer: Psyllium (Fiber supplementation).

Question 3: A $23$-year-old male with a $6$-month history of mucus-containing (non-bloody) diarrhea, bloating, and discomfort is diagnosed with IBS. What is the suggested pathogenesis? Answer: GI dysmotility.